Skip to main content
. 2018 Apr 24;10(2):53. doi: 10.3390/pharmaceutics10020053

Figure 6.

Figure 6

Plasma concentration–time profiles of (A) ITZ and (B) OH-ITZ after oral administration of the commercial capsules and the formulation of F1 (ITZ-HPMCAS) and F3 (ITZ-HPMCAS-15%TPGS). (Mean ± S.D., n = 6).